文献速递病毒性肝炎

雷迪帕韦联合索磷布韦固定剂量复方治疗急性丙型肝炎基因1型单一感染6周:开放标签单臂2期研究

Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.
PubMed 文献 · Lancet Infect Dis · 2016-10-28

这项在德国10个中心开展的前瞻性开放标签单臂2期研究纳入20例急性HCV基因1型单一感染成人,给予雷迪帕韦90mg联合索磷布韦400mg固定剂量复方每日一次治疗6周。所有20例(100%)患者均获得治疗结束后12周持续病毒学应答,治疗耐受性良好,无药物相关严重不良事件。

要点

  • 急性HCV基因1型感染接受雷迪帕韦联合索磷布韦6周治疗,SVR12达100%(20/20)。
  • 治疗耐受性良好,未发生药物相关严重不良事件。
  • 短疗程无干扰素方案或有助于在高危人群中阻断HCV传播。

核心结论

  • 雷迪帕韦联合索磷布韦治疗6周在急性HCV基因1型单一感染患者中耐受性良好且高度有效。
  • 短疗程治疗急性丙型肝炎可能预防HCV在高危人群中传播。

研究设计与样本

  • 前瞻性、开放标签、多中心、单臂试点研究,纳入德国10个中心的成人(≥18岁)急性HCV基因1型单一感染患者。
  • 患者接受雷迪帕韦90mg联合索磷布韦400mg固定剂量复方片每日一次,共6周。
  • 主要疗效终点为持续病毒学应答(治疗结束后12周HCV RNA检测不到),其他主要终点为安全性和耐受性;主要分析人群为至少接受一剂研究药物的全部患者。
  • 2014年11月19日至2015年11月10日期间共入组20例患者。

主要发现

  • 11例患者感染HCV基因1a型,9例感染基因1b型。
  • 全部20例(100%)患者均获得治疗结束后12周持续病毒学应答。
  • 治疗耐受性良好,无药物相关严重不良事件;截至治疗后12周共报告22例可能或很可能与药物相关的不良事件。
  • 发生1例严重不良事件,判定与研究药物无关(1例患者因交叉韧带断裂手术住院)。

临床怎么用

  • 对于急性HCV基因1型单一感染成人,可考虑雷迪帕韦联合索磷布韦固定剂量复方每日一次、疗程6周的无干扰素方案。
  • 短疗程治疗或可作为高危人群中预防HCV传播的策略。

局限性

  • 开放标签、单臂、试点研究设计,样本量仅20例,缺乏对照组。
  • 仅纳入HCV基因1型单一感染成人,结果外推至其他基因型或合并感染人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early treatment of acute hepatitis C virus (HCV) infection with interferon alfa is highly effective, but can be associated with frequent side-effects. We investigated the safety and efficacy of an interferon-free regimen for treatment of acute HCV infection. METHODS: In this prospective, open-label, multicentre, single-arm pilot study, we enrolled adults (≥18 years) with acute HCV genotype 1 monoinfection from ten centres in Germany. Patients were given ledipasvir (90 mg) plus sofosbuvir (400 mg) as a fixed-dose combination tablet once daily for 6 weeks. The primary efficacy outcome was the proportion of patients with sustained virological response (defined as undetectable HCV RNA 12 weeks after the end of treatment; other primary outcomes were safety and tolerability of ledipasvir plus sofosbuvir. The primary analysis population consisted of all patients who received at least one dose of study drug. Safety was also assessed in all patients who received at least one dose of the study drug. This trial is registered with ClinicalTrials.gov, number NCT02309918. FINDINGS: Between Nov 19, 2014, and Nov 10, 2015, we enrolled 20 patients. Median HCV RNA viral load at baseline was 4·04 log10 IU/mL (1·71-7·20); 11 patients were infected with HCV genotype 1a and nine patients with genotype 1b. All patients achieved a sustained virological response 12 weeks after the end of treatment (20 [100%] of 20 patients). Treatment was well tolerated; there were no drug-related serious adverse events. Up to 12 weeks after treatment, 22 possible or probable drug-related adverse events were reported. There was one serious adverse event, which was judged unrelated to the study drug; one patient was admitted to hospital for surgery of a ruptured cruciate ligament. INTERPRETATION: Treatment for 6 weeks with ledipasvir plus sofosbuvir was well tolerated and highly effective in patients with acute HCV genotype 1 monoinfection. Short-duration treatment of acute hepatitis C might prevent the spread of HCV in high-risk populations. FUNDING: Gilead Sciences, HepNet Study-House/German Liver Foundation, and German Centre for Infection Research (DZIF).

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Deterding K, Spinner CD, Schott E, et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis. 2016. PMID: 28029529. doi:10.1016/S1473-3099(16)30408-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。